<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112484">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01718366</url>
  </required_header>
  <id_info>
    <org_study_id>GFM-EXVD-AZA-2011-005623-41</org_study_id>
    <nct_id>NCT01718366</nct_id>
  </id_info>
  <brief_title>A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS</brief_title>
  <acronym>GFM-EXVD-AZA</acronym>
  <official_title>Phase I-II Study of Association of Deferasirox, Vitamin D and Azacytidine as Treatment of High Risk MDS (IPSS Int-2 and High)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determinate safety and response rate of the association Deferasirox -Vitamine D -
      Azacitidine in treatment of high risk MDS

      Deferasirox Exjade:

      The dose of Deferasirox will be assigned according to the ferritin level. Dose escalation is
      scheduled during the phase I, with 5 additional patients per group.

      The maximal tolerated dose of Deferasirox will be required for the phase II of the study.

      The first dose will be assigned according to the ferritin level of the patient at time of
      inclusion:

      5 mg/kg/d if the ferritin is &gt;300ng/ml and &lt; 1000ng/ml in Group 1 10 mg/kg/d if the ferritin
      is  ≥1000ng/ml) in Group 2

      Group 1 : Ferritin  300 to 1000ng /ml:

        -  cohort 1 : 5 mg/kg/d

        -  cohort 2 : 10mg/kg/d

        -  cohort 3 : 15 mg/kg/d

      Group 2 : Ferritin &gt; 1000ng /ml:

        -  cohort 1 : 10 mg/kg/d

        -  cohort 2 : 15mg/kg/d

        -  cohort 3 : 20 mg/kg/d

           5 patients will be treated by cohort. In absence of toxicity (extra-hematological
           toxicity grade 3 or 4 or hematological grade 4), 5 additional patients will be included
           in the next cohort.

      Deferasirox will be administrated once daily during all the study period. Uvedose will be
      administrated once weekly during all the study period (100.000 UI P.O).

      Azacitidine will be administrated sc at 75 mg/m²/d, during 7 days, J1 to J7 of each
      cycles(One cycle is 28 days)

      During phase I and II, Deferasirox will always be associated with Vitamin D and Azacitidine

      Patients will be received 6 cycles of treatment (except if progression, unacceptable
      toxicity or withdrawn of patients occured) After 3 and 6 cycles, an evaluation will be done
      to evaluate the efficacy of the treatment.

      No dose modification of deferasirox will be done after 3 cycles of treatment except in case
      of progression). After 6 cycles, patients with CR, PR, marrow CR or HI will be treated with
      the same dose of Deferasirox until progression .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deferasirox will be administrated once daily in the morning on an empty stomach, 30 minutes
      before meal.

      Deferasirox will be stopped if the ferritin level is under 100 ng/ml,and could be restarted
      is the ferritin level increase to 200 ng/ml

      Uvedose dose could be adjusted according to the phosphocalcic metabolism parameters and the
      plasma Vitamin D3 level.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To determine the maximal tolerated dose(MTD</measure>
    <time_frame>6 month of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>patient will be evaluable after at least one cycle. Treatment will be administrated during 6 month and responders will be treated until progression or death</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>MDS</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be included in 2 groups according to the ferritin level at time of inclusion.
Patients with the ferritin level &gt;300ng/ml and &lt; 1000ng/ml, will be included in Group 1.
5 patients in each cohort: Cohort 1: Deferasirox: 5mg/kg/d Cohort 2: Deferasirox: 10mg/kg/d Cohort 3: Deferasirox: 15mg/kg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be included in 2 groups according to the ferritin level at time of inclusion.
Patients with the ferritin level &gt; 1000ng/ml, will be included in Group 2.
5 patients in each cohort: Cohort 1: Deferasirox: 10mg/kg/d Cohort 2: Deferasirox: 15mg/kg/d Cohort 3: Deferasirox: 20mg/kg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferasirox, Vitamin D and Azacitidine</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Exjade</other_name>
    <other_name>Uvedose</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High risk MDS, according to OMS classification

          -  High risk CMML (WBC &lt; 13 G/L)

          -  AREBT of the FAB classification with less than 30% of blastes

          -  IPSS&gt;=1.5 (int-2 and high risk)

          -  Age &gt;=18y

          -  Performance status&lt;=2 (ECOG)

          -  Bilirubin and transaminase &lt; 1.5 x ULN

          -  Normal renal function

          -  Patient not eligible for Allogeneic stem cell transplant

          -  Male and female patients must use an effective contraceptive method during the study
             and for a minimum of 3 months after study treatment.

          -  Agree the need for the use of a condom if engaged in sexual activity with a pregnant
             woman or a woman of childbearing potential. during the entire period of treatment,
             even if disruption of treatment and during 3 months after end of treatment

          -  Male patient: Agree not to conceive during treatment and study drug therapy
             (including doses interruptions) and for 3 months after the end of the study drug
             therapy

          -  Agree not to donate semen during study drug therapy and for one week after end of
             study drug therapy.

          -  Agree  to learn about the procedures for preservation of sperm,before starting
             treatment

          -  Patient be able to adhere to the study visit schedule and other protocol requirements

        Exclusion Criteria:

          -  Active infection or uncontrolled disease

          -  Use of cytotoxic chemotherapeutic agents or experimental agents(agents that are not
             commercially available) for the treatment of MDS within 28 days. In case of used of
             cytotoxic chemotherapeutic agents or hypomethylating agent a wash out of 3 mont is
             required.

          -  Active Cancer or Cancer within one year before inclusion

          -  Previous calcic urinary lithiasis

          -  Previous hyperparathyroid primitive disease or uncontrolled

          -  Hypercalcemia, hyperphosphoremia, hypervitaminosis D

          -  Patient already include in another experimental study

          -  Active infection by HIV, hepatite B or C

          -  Pregnant or lactating females

          -  Patient not able (medical/psychiatric) to understand and sign the written consent

          -  Patients with a ferritin level less than 300ng/ml

          -  Patient eligible for an Allogeneic stem cell transplant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Hermine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Necker Hospital (Paris)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Fenaux, MD</last_name>
    <role>Study Director</role>
    <affiliation>Saint Louis Hospital (Paris)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipe Suarez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Necker Hospital (Paris)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felipe Suarez, MD</last_name>
    <phone>033144495286</phone>
    <email>felipe.suarez@nck.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benedicte SAMEY, CRA</last_name>
    <phone>033148955590</phone>
    <email>benedicte.samey@avc.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier de La Cote Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Banos, MD</last_name>
      <phone>033559443832</phone>
      <email>abanos@ch-cotebasque.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Banos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten Braun, MD</last_name>
      <phone>33148957051</phone>
      <email>thorsten.braun@avc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Thorsten Braun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Rose, MD</last_name>
      <phone>33320874532</phone>
      <email>rose.christian@ghicl.net</email>
    </contact>
    <investigator>
      <last_name>Christian Rose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Dreyfus, MD</last_name>
      <phone>33158411996</phone>
      <email>francois.dreyfus@cch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>François Dreyfus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Fenaux, MD</last_name>
      <phone>033170207022</phone>
      <email>pierre.fenaux@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Fenaux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Hermine, MD</last_name>
      <phone>33144495283</phone>
      <email>olivier.hermine@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Hermine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felipe Suarez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>October 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
